Radiopharm Theranostics Ltd
RAD 204
PD-L1-driven malignancies
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for RAD 204 in PD-L1-driven malignancies are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The second cohort has been completed and, following DSMC approval, the Company has proceeded to a third cohort at an updated dose level of 90 mCi.”